Spybiotech seeks new vaccines

Novel vaccine technologies have understandably received much attention over the past few years, with the pandemic prompting an uptick in investment. One beneficiary was Spybiotech, an Oxford University spinout that reckons it has an answer to one of the biggest problems with vaccines that are based on virus-like particles.

The group is poised to take its first candidate into the clinic, against cytomegalovirus, and its new chairman, Eddie Gray, tells Evaluate Vantage he hopes to see “game-changing” immunogenicity.